Envestnet Asset Management INC Has Boosted Gilead Sciences INC (GILD) Position by $35.06 Million as Market Valuation Rose

September 30, 2018 - By Mark Babin

Gilead Sciences, Inc. (NASDAQ:GILD) LogoInvestors sentiment decreased to 0.75 in 2018 Q2. Its down 0.13, from 0.88 in 2018Q1. It turned negative, as 75 investors sold GILD shares while 532 reduced holdings. 89 funds opened positions while 366 raised stakes. 977.84 million shares or 0.14% more from 976.44 million shares in 2018Q1 were reported. Cohen Capital Management stated it has 0.05% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 749,727 shares. Columbia Asset Mngmt has invested 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD). First Interstate Bancorp holds 1.71% or 109,258 shares in its portfolio. Lord Abbett & Communication Ltd Llc accumulated 423,438 shares. Choate Advsr holds 0.04% or 9,198 shares. Sandy Spring Bancorporation stated it has 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Reynders Mcveigh Capital Mngmt Limited Liability Company holds 78,431 shares. Avalon Advsr Ltd Company reported 1.02% stake. Aqr Cap Limited Liability stated it has 8.89M shares. Middleton Inc Ma has invested 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Capital Ok holds 0.46% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 108,334 shares. Endurant Limited Partnership, California-based fund reported 82,863 shares. Highstreet Asset Mngmt reported 48,756 shares. Tudor Inv Corp Et Al invested in 27,855 shares.

Since April 2, 2018, it had 0 buys, and 9 sales for $16.38 million activity. Cogan John Francis sold $434,384 worth of stock or 5,833 shares.

Envestnet Asset Management Inc increased its stake in Gilead Sciences Inc (GILD) by 589.07% based on its latest 2018Q2 regulatory filing with the SEC. Envestnet Asset Management Inc bought 500,802 shares as the company’s stock rose 3.76% with the market. The institutional investor held 585,817 shares of the health care company at the end of 2018Q2, valued at $41.50M, up from 85,015 at the end of the previous reported quarter. Envestnet Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $100.09 billion market cap company. The stock increased 0.82% or $0.63 during the last trading session, reaching $77.21. About 6.10 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 12.47% since September 30, 2017 and is downtrending. It has underperformed by 28.09% the S&P500.

Envestnet Asset Management Inc, which manages about $60.39B and $43.79B US Long portfolio, decreased its stake in Select Sector Spdr Tr (XLI) by 44,447 shares to 340,998 shares, valued at $24.43M in 2018Q2, according to the filing. It also reduced its holding in Vanguard Intl Equity Index F (VEU) by 785,606 shares in the quarter, leaving it with 1.93 million shares, and cut its stake in Ishares Inc (EZU).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Ebola outbreak spreading in Congo” on September 07, 2018, also Seekingalpha.com with their article: “Gilead And NASH: New Heydays Are Ahead” published on September 02, 2018, Seekingalpha.com published: “Gilead Is On Hold For Now” on September 14, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Forming A Base?” published on September 18, 2018 as well as Nasdaq.com‘s news article titled: “Analysis: Positioning to Benefit within Enerplus, ExlService, Gilead Sciences, 51job, QUALCOMM, and Perrigo …” with publication date: September 27, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Among 8 analysts covering Gilead Sciences (NASDAQ:GILD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Gilead Sciences had 9 analyst reports since May 2, 2018 according to SRatingsIntel. Piper Jaffray initiated it with “Buy” rating and $8500 target in Wednesday, May 30 report. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Equal-Weight” rating given on Wednesday, May 2 by Morgan Stanley. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, May 2 with “Buy” rating. The firm earned “Overweight” rating on Thursday, May 31 by PiperJaffray. The company was maintained on Wednesday, May 2 by Leerink Swann. The company was downgraded on Thursday, July 26 by Robert W. Baird. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, May 2 report. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, July 26 report.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: